Business Context and Reporting Period
Actinium Pharmaceuticals, Inc. (ATNM) filed this Form 8-K on March 27, 2020. The filing addresses the company's decision to delay the submission of its Annual Report on Form 10-K for the fiscal year ended December 31, 2019.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document serves as a notification of a filing delay rather than a financial results report.
Material Changes and Operational Impact
- Reporting Delay: The company is utilizing an SEC Order (Release No. 34-88318) to extend the deadline for its 2019 10-K filing.
- Operational Disruptions: The COVID-19 pandemic has caused severe disruptions in transportation and limited access to the company's facility.
- Resource Constraints: The company faces limited support from staff and professional advisors, which has delayed the completion of its annual audit.
Outlook, Risks, and Management Commentary
Expected Filing Date: Management expects to file the delayed 10-K no later than May 14, 2020, which is 45 days after the original deadline of March 30, 2020.
Risk Factors: The company is adding a new risk factor to its upcoming report stating that uncontrollable events like the COVID-19 pandemic are likely to negatively affect operations. Specific impacts include:
- Social distancing, travel bans, and quarantine measures.
- Limited access to facilities, management, and support staff.
- Adverse effects on financial condition and the ability to react timely to mitigate impacts.
- Hampered efforts to provide timely information to investors and comply with SEC filing obligations.
Investor Verification Checklist
- Verify the actual filing date of the 2019 Form 10-K to ensure it was submitted by the May 14, 2020 deadline.
- Review the final 10-K for updated financial statements and the full text of the new COVID-19 risk factor.
- Monitor subsequent filings for updates on the extent of operational and financial impact caused by the pandemic.
- Confirm the status of the company's audit process and any related going concern disclosures.